Impact of vitamin D on the hospitalization rate of Crohn's disease patients seen at a tertiary care center

Table 1 Characteristics of Crohn’s disease patients by mean vitamin D level

	Mean < 30 (n = 115)	Mean ≥ 30 (n = 81)
Age, (mean ± SD, yr)	45.50 (15.07)	54.26 (17.63)
DoD	17.83 (11.77)	22.58 (14.50)
Race
Caucasian	66.96%	87.65%
African-American	31.30%	12.35%
Others	1.74%	0.00%
Female	61.74%	71.6%
BMI
Low (< 18.5)	11.30%	8.64%
Normal (18.5-24.9)	40.00%	41.98%
Over Weight (25-29.9)	20.00%	27.16%
Obese (≥ 30)	28.70%	22.22%
Smoking	26.96	11.11
Steroids	51.30	45.68
Immune modulators	84.35%	76.54%
Biologicals	61.74%	51.85%
Thiopurines	61.74%	51.85%
Methotrexate	20.87	13.58

DoD: Duration of disease; BMI: Body mass index.

Table 2 Crude, partially adjusted, fully adjusted rate ratios for Crohn’s disease- related hospitalization

	CD-related number of hospitalizations/total person years	Hospitalization rate (95%CI)1	IRR (95%CI)
			Model 1	Model 2	Model 3
Overall	372/1610	23.11 (20.87, 25.58)
Mean Vitamin D level ≥ 30 mg/dL	101/712	14.19 (11.67, 17.24)	1 (reference)	1 (reference)	1 (reference)
Mean Vitamin D level < 30 mg/dL	271/898	30.18 (26.79, 33.99)	2.13(1.69, 2.67)	1.76 (1.38, 2.24)	1.44 (1.11, 1.87)

¹Per 100 person-year. Model 1 is unadjusted; Model 2 is partially adjusted for age, sex, race, duration of disease; Model 3 is fully adjusted for age, sex, race, duration of disease, BMI, smoking, steroids, traditional and biological, immune modulators, thiopurines, methotrexate. CD: Crohn’s disease; BMI: Body mass index.